Verrica Pharmaceuticals Inc. (VRCA)

Market Cap	106.02M
Revenue (ttm)	8.96M
Net Income (ttm)	-28.10M
Shares Out	40.30M
EPS (ttm)	-1.55
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	64,316
Open	2.62
Previous Close	2.58
Day's Range	2.6 - 2.78
52-Week Range	1.77 - 10.98
Beta	1.93
Analysts	Buy
Price Target	11.83 (+346.4%)
Earnings Date	Nov 11, 2022

About VRCA

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agr...

• Industry: Pharmaceuticals
• IPO Date: Jun 15, 2018
• CEO: Ted White
• Employees: 38
• Stock Exchange: NASDAQ
• Ticker Symbol: VRCA

Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for VRCA stock is "Buy." The 12-month stock price forecast is 11.83, which is an increase of 346.42% from the latest price.

Price Target

$11.83

(346.42% upside)

Analyst Consensus: Buy

Stock Forecasts